In a column published on The Health Care Blog, Northeastern University Professor of Management, Healthcare Systems, and Health Policy Timothy Hoff says value is focused too heavily on payment reform and cost reduction as it puts patient experience on the back burner. "In short, right now 'value' […]
Podcast Features Banner-Aetna’s EVP
Banner-Aetna Executive Vice President Robert Groves was the featured guest of a Saturday podcast by Red Hot Healthcare. Red Hot Healthcare says the hour-long episode was "one of the best back-and-forth engagements in show history." Groves discussed a range of topics, including:Personal […]
Innovative drugs: Mapping the Pricing, Reimbursement and HTA Landscape
Widespread patient access to innovative new products is being frustrated in non-U.S. markets by health technology assessments (HTA). Between January 2016 and June 2017, 58 innovative medicines were approved and launched in the U.S. — but what of their status elsewhere? For example, only 35 of the […]
Massachusetts Sets A New Standard Establishing Transparency for Healthcare Services
Massachusetts is one of the first states to pass a law requiring healthcare providers and payers to make medical service prices accessible to the public, but setting quality standards and wariness among providers are significant obstacles. Read more here. (Source: Christopher Cheney, Media Health […]
72% Of All New Products Fail – How To Keep Your Product On Top!
Global strategy consultancy group, Simon-Kucher & Partners, in collaboration with the independent Professional Pricing Society, conducted the Global Pricing Study 2014, and found that 72% of all new products flop! This is an alarming problem highlighting the need for pricing and marketing to be […]
The Politics Of Pharma Pricing: Are We Asking The Right Questions?
Sovaldi has had more than its fair share of attention this year, but most of it seems to be centered around the pricing and not the benefits. When trying to understand the reasoning behind the high price, are the right questions being asked? Can the price be justified when looking at long term cuts […]
IQWiG Finds Added Benefit For Novaris’ Jakavi In Myelofibrosis
In an early benefit assessment under the German Act on the Reform of the Market for Medicinal Products… Free trial or subscription is required to continue reading this article, here. (Source: thepharmaletter, 8/20/14). […]
Are U.S. Cancer Patients Receiving Better Care Than Europeans?
A New Tufts Study on oncology market access has found that U.S. cancer patients get faster access to more oncology drugs than European patients, but is more better? How does comparative effectiveness research in the U.S. and the European's Evidence-based system fit into this? Who is getting the best […]
Are You Managing Your Market Access Team For Success?
The demands on market access teams are growing rapidly as the specific needs of key stakeholders grow ever greater. How do you structure and manage your market access team for best results and evaluate their success? Learn the prerequisites for market access success through key insights from […]
NICE Approves Sovaldi, But Not For Everyone
After providing additional information requested by the National Institute for Health and Care Excellence, Gilead Sciences' new hepatitis C pill is now being provisionally recommended as a cost-effective treatment for some people with chronic hepatitis C. Sovaldi will be priced at 35,000 pounds […]
